Abarelix

Jump to: navigation, search


Abarelix
Abarelix.svg
Clinical data
ATC code
Pharmacokinetic data
Protein binding96–99%
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC72H95ClN14O14
Molar mass1416.06 g/mol

WikiDoc Resources for Abarelix

Articles

Most recent articles on Abarelix

Most cited articles on Abarelix

Review articles on Abarelix

Articles on Abarelix in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Abarelix

Images of Abarelix

Photos of Abarelix

Podcasts & MP3s on Abarelix

Videos on Abarelix

Evidence Based Medicine

Cochrane Collaboration on Abarelix

Bandolier on Abarelix

TRIP on Abarelix

Clinical Trials

Ongoing Trials on Abarelix at Clinical Trials.gov

Trial results on Abarelix

Clinical Trials on Abarelix at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Abarelix

NICE Guidance on Abarelix

NHS PRODIGY Guidance

FDA on Abarelix

CDC on Abarelix

Books

Books on Abarelix

News

Abarelix in the news

Be alerted to news on Abarelix

News trends on Abarelix

Commentary

Blogs on Abarelix

Definitions

Definitions of Abarelix

Patient Resources / Community

Patient resources on Abarelix

Discussion groups on Abarelix

Patient Handouts on Abarelix

Directions to Hospitals Treating Abarelix

Risk calculators and risk factors for Abarelix

Healthcare Provider Resources

Symptoms of Abarelix

Causes & Risk Factors for Abarelix

Diagnostic studies for Abarelix

Treatment of Abarelix

Continuing Medical Education (CME)

CME Programs on Abarelix

International

Abarelix en Espanol

Abarelix en Francais

Business

Abarelix in the Marketplace

Patents on Abarelix

Experimental / Informatics

List of terms related to Abarelix

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.

References



Linked-in.jpg